Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
August 5, 2021 7:51 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $2.33 million versus the consensus estimate of $2.12 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
... More